BRIEF-Spark Therapeutics and Pfizer announce data from first cohort in Hemophilia B Phase 1/2 trial
July 25, 2016 at 08:55 AM EDT
* Spark Therapeutics and Pfizer announce updated data from first cohort in Hemophilia B phase 1/2 trial demonstrating consistent, sustained therapeutic levels of factor ix activity